Teitur Trophics Hosts 2nd Scientific Advisory Board Meeting for TT-P34

Teitur Trophics has hosted its second Scientific Advisory Board (SAB) meeting for the company’s lead program, TT-P34, a potential disease-modifying therapy for Parkinson’s disease.

The meeting focused on an in-depth discussion of biomarker endpoint measurements for the upcoming Phase II clinical trial in Parkinson’s disease. During the session, leading experts in the field provided valuable insights to further refine the Phase II clinical strategy for TT-P34.

Discussions centered on biomarker-driven endpoints that will guide the next stage of clinical development, including alpha-synuclein species in CSF, neuropeptide signatures, imaging-based markers of neurodegeneration, and clinical progression metrics.

Teitur Trophics was honored to receive strategic input from Dr. Ronald Postuma (McGill University), Dr. Charlotte Teunissen (Amsterdam UMC), Dr. Björn Falkenburger (University Hospital Dresden), and Dr. Pierandrea Muglia (CMO, Saniona). Their combined expertise in biomarker validation, neuroimaging, and translational neurology plays a pivotal role in shaping a robust and differentiated clinical trial design.

This meeting marks an important milestone in advancing TT-P34 toward Phase II. Teitur Trophics remains committed to advancing biomarker-led innovation and strengthening collaborations with the scientific and clinical community as preparations for the Phase II trial move forward.

‍